LivaNova’s Perceval Sutureless Aortic Heart Valve Approved in Japan
“With this approval for Perceval, an innovative and trusted valve platform, we are able to provide patients and clinicians in
The Perceval sutureless valve is supported by a strong body of evidence with more than 10 years of clinical experience. The valve is specifically designed to reduce the physiological impact of aortic valve replacement and improve patient outcomes. Perceval is also designed to be highly versatile and suitable for a wide range of surgical approaches, including traditional and minimally invasive.
“At LivaNova, we are committed to enhancing patient care around the world, and will continue to address the increasing global need for advanced aortic valve solutions,” said
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 3,500 employees. LivaNova operates as two businesses: Cardiac Surgery and Neuromodulation, with operating headquarters in Mirandola (
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to
All information in this news release is as of the date of its release.
LivaNova PLC Investor Relations and Media
Karen King, +1 (281) 228-7262
Vice President, Investor Relations & Corporate Communications
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications – Products & Therapies